Changzhou Ruiming Pharmaceutical Co., Ltd. is located at No.1558 Longjiang North Road, Chunjiang Town, Xinbei District, Changzhou City, Jiangsu Province. Founded in 2005, it is a pharmaceutical enterprise specializing in the R&D, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and preparations related to cardiovascular, urinary, respiratory and digestive systems.

The company is adjacent to the Shanghai–Nanjing Expressway with convenient transportation and superior environment. It manufactures APIs as specified in its Drug Production License. The production scope covers APIs (Propafenone Hydrochloride, Tamsulosin Hydrochloride, Felodipine, Amlodipine Besilate, Levoamlodipine Besylate).

Covering an area of 25,000 square meters, the company is equipped with synthesis workshops, final purification, drying & packaging workshops (GMP-compliant), liquid raw material warehouses, solid raw material warehouses, intermediate warehouses and finished product warehouses, etc.

The company owns two API production lines and one solid preparation production line. The production process equipment and quality testing instruments deployed meet the current requirements of domestic pharmaceutical production and quality management specifications, capable of supporting production and quality control for existing products.

To date, the company has six APIs with registration status “A” that have passed GMP compliance inspections. Among them, Amlodipine Besilate has obtained certifications from EDQM (European Directorate for the Quality of Medicines & HealthCare) and Japan PMDA; Tamsulosin Hydrochloride has passed FDA on-site inspection.
In 2024, the company obtained the marketing approval for Levoamlodipine Besylate Tablets.
It was awarded the title of “Gazelle Enterprise in the Southern Jiangsu National Independent Innovation Demonstration Zone” in 2019, and recognized as a national-level Specialized, Refined, Differential and Innovative (SRDI) “Little Giant” enterprise in 2024.

The production lines for the audited material Amlodipine Besilate include the synthesis workshop and the final purification, drying & packaging workshop, mainly for formulation projects.
Major production equipment includes amlodipine base hydrolysis reactors, amlodipine besilate salt-forming reactors, centrifuges, decolorization reactors, crystallization reactors, double cone rotary vacuum dryers, high-efficiency pulverizers, double cone blenders, etc.
The packing specification is 25 KG per drum, with an annual production capacity of 180 tons.